Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Active, not recruiting · NCT05923190 · Registry updated 2026-03-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Active, not recruiting | Phase 2 | 2026-03-19 | NCT05923190 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fox Chase Cancer Center | 58 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center - Philadelphia | Philadelphia | United States | 10 |